$VYGR
Voyager Therapeutics, Inc.

2020 Form 10-K Financial Statement

#000155837021001865 Filed on February 25, 2021

View on sec.gov

Income Statement

Concept 2020 2019 Q4 2019
Revenue $171.1M $32.67M $104.4M
YoY Change 63.93% 1527.19% 1270.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $35.00M $9.900M $36.30M
YoY Change -3.58% 19.28% 7.4%
% of Gross Profit
Research & Development $108.8M $36.60M $119.7M
YoY Change -9.17% 116.57% 84.48%
% of Gross Profit
Depreciation & Amortization $3.800M $800.0K $2.800M
YoY Change 35.71% 33.33% 33.33%
% of Gross Profit
Operating Expenses $143.7M $46.44M $156.1M
YoY Change -7.9% 84.52% 58.1%
Operating Profit $27.38M -$13.77M -$51.68M
YoY Change -152.99% -40.56% -43.27%
Interest Expense $1.659M $1.400M $6.457M
YoY Change -74.31% 55.56% 95.08%
% of Operating Profit 6.06%
Other Income/Expense, Net $9.357M -$200.0K $8.082M
YoY Change 15.78% -33.33% 207.65%
Pretax Income $36.74M -$12.60M -$43.60M
YoY Change -184.27% -44.0% -50.72%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $36.74M -$12.57M -$43.60M
YoY Change -184.27% -44.19% -50.62%
Net Earnings / Revenue 21.47% -38.48% -41.76%
Basic Earnings Per Share $0.99 -$1.21
Diluted Earnings Per Share $0.98 -$342.4K -$1.21
COMMON SHARES
Basic Shares Outstanding 37.13M 37.07M 35.90M
Diluted Shares Outstanding 37.35M 35.90M

Balance Sheet

Concept 2020 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $181.1M $281.5M $281.5M
YoY Change -35.67% 80.68% 80.68%
Cash & Equivalents $104.4M $86.04M $86.00M
Short-Term Investments $76.70M $195.5M $195.5M
Other Short-Term Assets $8.500M $1.398M $4.200M
YoY Change 102.38% 2.79% -35.38%
Inventory
Prepaid Expenses
Receivables $8.000M $18.50M $18.50M
Other Receivables $100.0K $0.00 $500.0K
Total Short-Term Assets $197.8M $304.7M $304.7M
YoY Change -35.08% 87.5% 87.51%
LONG-TERM ASSETS
Property, Plant & Equipment $61.50M $17.99M $46.50M
YoY Change 32.26% 40.83% 263.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $1.900M $1.900M
YoY Change -100.0% 216.67% 216.67%
Other Assets $2.300M $1.700M $1.700M
YoY Change 35.29% 54.55% 54.55%
Total Long-Term Assets $63.80M $50.10M $50.10M
YoY Change 27.35% 244.38% 245.52%
TOTAL ASSETS
Total Short-Term Assets $197.8M $304.7M $304.7M
Total Long-Term Assets $63.80M $50.10M $50.10M
Total Assets $261.6M $354.8M $354.8M
YoY Change -26.27% 100.4% 100.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $4.070M $4.100M
YoY Change -85.37% 292.1% 310.0%
Accrued Expenses $18.40M $21.52M $24.70M
YoY Change -25.51% 119.82% 152.04%
Deferred Revenue $47.23M
YoY Change 126.57%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.80M $76.01M $76.00M
YoY Change -64.74% 139.99% 139.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $80.50M $31.98M $179.2M
YoY Change -55.08% 376.47% 81.19%
Total Long-Term Liabilities $80.50M $31.98M $179.2M
YoY Change -55.08% 376.47% 81.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.80M $76.01M $76.00M
Total Long-Term Liabilities $80.50M $31.98M $179.2M
Total Liabilities $107.3M $255.2M $255.2M
YoY Change -57.95% 95.47% 95.41%
SHAREHOLDERS EQUITY
Retained Earnings -$312.6M
YoY Change 16.2%
Common Stock $37.00K
YoY Change 15.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $154.3M $99.51M $99.50M
YoY Change
Total Liabilities & Shareholders Equity $261.6M $354.8M $354.8M
YoY Change -26.27% 100.4% 100.45%

Cashflow Statement

Concept 2020 2019 Q4 2019
OPERATING ACTIVITIES
Net Income $36.74M -$12.57M -$43.60M
YoY Change -184.27% -44.19% -50.62%
Depreciation, Depletion And Amortization $3.800M $800.0K $2.800M
YoY Change 35.71% 33.33% 33.33%
Cash From Operating Activities -$96.72M -$23.30M $48.67M
YoY Change -298.73% -4.51% -406.33%
INVESTING ACTIVITIES
Capital Expenditures $12.10M -$3.400M $7.718M
YoY Change 56.74% 580.0% 79.28%
Acquisitions
YoY Change
Other Investing Activities $125.1M $29.80M -$82.76M
YoY Change -251.15% 2.05% -368.96%
Cash From Investing Activities $113.0M $26.40M -$90.48M
YoY Change -224.89% -8.01% -441.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.163M 300.0K 80.99M
YoY Change -96.09% -25.0% 1605.5%
NET CHANGE
Cash From Operating Activities -96.72M -23.30M 48.67M
Cash From Investing Activities 113.0M 26.40M -90.48M
Cash From Financing Activities 3.163M 300.0K 80.99M
Net Change In Cash 19.44M 3.400M 39.18M
YoY Change -50.38% -27.66% 155.61%
FREE CASH FLOW
Cash From Operating Activities -$96.72M -$23.30M $48.67M
Capital Expenditures $12.10M -$3.400M $7.718M
Free Cash Flow -$108.8M -$19.90M $40.95M
YoY Change -365.73% -16.74% -302.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei City Area Code
CityAreaCode
857
CY2020 dei Local Phone Number
LocalPhoneNumber
259-5340
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2019Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37368027
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36865116
CY2020 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2019Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2020Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001640266
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-37625
CY2020 dei Entity Registrant Name
EntityRegistrantName
Voyager Therapeutics, Inc.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3003182
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
75 Sidney Street
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2020 dei Trading Symbol
TradingSymbol
VYGR
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
291700000
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37653805
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104440000
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8012000
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
18496000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86042000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
76698000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
195491000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44410000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31976000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8619000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4630000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
197769000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
304659000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25435000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17986000
CY2020Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
2316000
CY2019Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1723000
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1920000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36064000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28472000
CY2020Q4 us-gaap Assets
Assets
261584000
CY2019Q4 us-gaap Assets
Assets
354760000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
634000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4070000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14205000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21516000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4198000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3193000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7729000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
47233000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26766000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
76012000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
36088000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
147260000
CY2020Q4 us-gaap Liabilities
Liabilities
107264000
CY2019Q4 us-gaap Liabilities
Liabilities
255248000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37368027
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36865116
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
430324000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
412227000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-134000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-104000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275907000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
154320000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
99512000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261584000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-312648000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
29000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
34000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1625000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-683000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
354760000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
171128000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104391000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7619000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
108753000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
119735000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64905000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34991000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36335000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33809000
CY2020 us-gaap Operating Expenses
OperatingExpenses
143744000
CY2019 us-gaap Operating Expenses
OperatingExpenses
156070000
CY2018 us-gaap Operating Expenses
OperatingExpenses
98714000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
27384000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-51679000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-91095000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1659000
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6457000
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3310000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7698000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9357000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8082000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2627000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
36741000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43597000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-88468000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-180000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
36741000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-43597000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-88288000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
29000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
34000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-30000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
36711000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43568000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-88254000
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.99
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.75
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.98
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.75
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37132447
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35898266
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32065781
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37348514
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35898266
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32065781
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
134051000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3891000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
9000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
969000
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
15710000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
34000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-88288000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
46446000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2714000
CY2019 vygr Stock Issued During Period Value Collaboration Agreement
StockIssuedDuringPeriodValueCollaborationAgreement
77617000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
663000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
15640000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
29000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-43597000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
99512000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2319000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1279000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
14499000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
36741000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
154320000
CY2020 us-gaap Profit Loss
ProfitLoss
36741000
CY2019 us-gaap Profit Loss
ProfitLoss
-43597000
CY2018 us-gaap Profit Loss
ProfitLoss
-88288000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
14934000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
15640000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
15710000
CY2020 us-gaap Depreciation
Depreciation
3817000
CY2019 us-gaap Depreciation
Depreciation
2765000
CY2018 us-gaap Depreciation
Depreciation
2117000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-27000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3584000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2163000
CY2019 vygr In Kind Research And Development Expenses
InKindResearchAndDevelopmentExpenses
616000
CY2018 vygr In Kind Research And Development Expenses
InKindResearchAndDevelopmentExpenses
176000
CY2018 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-52000
CY2020 vygr Common Stock And Warrants To Purchase Equity Securities
CommonStockAndWarrantsToPurchaseEquitySecurities
-7698000
CY2019 vygr Common Stock And Warrants To Purchase Equity Securities
CommonStockAndWarrantsToPurchaseEquitySecurities
-1612000
CY2018 vygr Common Stock And Warrants To Purchase Equity Securities
CommonStockAndWarrantsToPurchaseEquitySecurities
807000
CY2020 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-10484000
CY2019 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
18496000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
551000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1675000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3937000
CY2020 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
7592000
CY2019 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-2951000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-275000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2714000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3889000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2319000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
343000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
180000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3436000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2598000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-282000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6480000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
11728000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1600000
CY2020 vygr Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
13439000
CY2019 vygr Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-2506000
CY2018 vygr Increase Decrease In Deferred Lease Incentive Credit From Lessor
IncreaseDecreaseInDeferredLeaseIncentiveCreditFromLessor
-321000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-150676000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
80831000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
61380000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-96716000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
48666000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15887000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12097000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7718000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4305000
CY2019 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
172000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
70403000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
494231000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
333228000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
195495000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
411300000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
364000000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
112995000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90477000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26467000
CY2019 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
77617000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
844000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
663000
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
860000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3163000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80994000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4749000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19442000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
39183000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15329000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86777000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47594000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32265000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106219000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86777000
CY2020 vygr Lease Exchange Cash Flow Amount
LeaseExchangeCashFlowAmount
10818000
CY2019 vygr Lease Exchange Cash Flow Amount
LeaseExchangeCashFlowAmount
30964000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
831000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
434000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
300000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47594000
CY2018 vygr Supplemental Cash Noncash Impact Of Accounting New Accounting Standards
SupplementalCashNoncashImpactOfAccountingNewAccountingStandards
-20050000
CY2019Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
28000
CY2019Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
275714000
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">VOYAGER THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Voyager Therapeutics, Inc. (the “Company”) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. The Company is focused on neurological diseases where it believes an adeno-associated virus (“AAV”) gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The Company has built a gene therapy platform that it believes positions itself to be a leading company at the intersection of AAV gene therapy and severe neurological disease. The Company’s gene therapy platform enables it to engineer, optimize, manufacture and deliver its AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Company is working to identify novel AAV capsids, which are the outer viral protein shells that enclose the genetic material of the virus payload. The Company’s team of experts in the fields of AAV gene therapy and neuroscience first identifies and selects severe neurological diseases that are well-suited for treatment using AAV gene therapy. The Company then engineers and optimizes AAV vectors for delivery of the virus payload to the targeted tissue or cells. The Company’s manufacturing process employs an established system that it believes will enable production of high quality AAV vectors at commercial-scale. In addition to the Company’s capsid optimization efforts, it leverages novel delivery paradigms, established routes of administration, and advances in dosing techniques to optimize delivery of its AAV gene therapies to target tissues, regions and cell types that are critical to the disease of interest. The Company believes it can achieve this directly, with targeted infusions to discrete regions of the brain, the spinal cord, or systemically, in conjunction with its novel capsids.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s business strategy focuses on discovering, developing, manufacturing and commercializing its gene therapy programs. As part of this strategy, the Company has developed core competencies specific to AAV gene therapy development and manufacturing. This business strategy also includes business development activities that may include in-licensing activities or partnering certain programs in certain geographies with collaborators, as the Company has demonstrated through its ongoing <span style="background-color:#ffffff;">collaboration with Neurocrine Biosciences, Inc. (the “Neurocrine Collaboration Agreement”)</span>. The Company is devoting substantially all of its efforts to product research and development, market development, and raising capital. The Company is subject to risks common to companies in the biotechnology and gene therapy industries, including but not limited to, the need to obtain sufficient capital to continue to fund its operations, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary information and technology, protection against data breaches and other cybersecurity threats, compliance with government regulations, development by competitors of technological innovations, and ability to transition from pilot-scale manufacturing to large-scale production of products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred annual net operating losses in every year prior to 2020. As of December 31, 2020, the Company had an accumulated deficit of $275.9 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from its prior collaborations with Sanofi Genzyme Corporation (“Sanofi Genzyme”), AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company (collectively, “AbbVie”), and its ongoing collaboration with Neurocrine Biosciences, Inc. (“Neurocrine”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable debt securities, as well as ongoing <span style="background-color:#ffffff;">reimbursement amounts expected from development costs related to the Neurocrine Collaboration Agreement, </span>will enable the Company to meet its planned operating expenses and capital expenditure re<span style="background-color:#ffffff;">quirements</span> into mid-2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenue from collaborative partners on terms acceptable to the Company, on a timely basis </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</p>
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275900000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</p>
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings
0
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
71568000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5136000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
76698000
CY2020Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
175560000
CY2020Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Gain Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedGainBeforeTax
5136000
CY2020Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
6000
CY2020Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
180690000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
196687000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
752000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
197411000
CY2019Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
274990000
CY2019Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Gain Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedGainBeforeTax
752000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1779000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1800000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
700000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104440000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86042000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46859000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
735000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
735000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106219000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86777000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47594000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35898266
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35898266
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32065781
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
216068
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37348514
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6064344
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5949201
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4460446
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
36741000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43597000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-88288000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37132447
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35898266
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32065781
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37132447
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32065781
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has no financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign currency hedging arrangements. Financial instruments that potentially subject the Company to a concentration of credit risk are cash and cash equivalents. The Company’s cash is held in accounts at financial institutions that may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Suppliers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is dependent on third-party manufacturers to supply certain products for research and development activities in its programs. In particular, the Company relies on a sole manufacturer to supply it with specific vectors related to the Company’s research and development programs.</p>
CY2020Q4 vygr Financial Instruments With Off Balance Sheet Risk Value
FinancialInstrumentsWithOffBalanceSheetRiskValue
0
CY2019 us-gaap Depreciation
Depreciation
2800000
CY2020Q4 vygr Warrants To Purchase Equity Securities
WarrantsToPurchaseEquitySecurities
3816000
CY2019Q4 vygr Warrants To Purchase Equity Securities
WarrantsToPurchaseEquitySecurities
554000
CY2020Q4 vygr Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
1674000
CY2019Q4 vygr Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
1999000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1575000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1398000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1459000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
203000
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
95000
CY2019Q4 us-gaap Interest Receivable
InterestReceivable
476000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8619000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4630000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37005000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25643000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11570000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7657000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25435000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17986000
CY2020 us-gaap Depreciation
Depreciation
3800000
CY2018 us-gaap Depreciation
Depreciation
2100000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1800000
CY2020Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6624000
CY2019Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
13248000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5857000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5733000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1153000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
897000
CY2020Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
496000
CY2019Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
1386000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
75000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
252000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14205000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21516000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7822000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8469000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8723000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8985000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
9644000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4198000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3193000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43409000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30975000
CY2020Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2019Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44410000
CY2020Q4 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.080
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000000.0
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3193000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
19945000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
63588000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15981000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
47607000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4198000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43409000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
47607000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
6200000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
5700000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y9M18D
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4198000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31976000
CY2020 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
18496000
CY2020 vygr Additions To Contract With Customer Assets
AdditionsToContractWithCustomerAssets
35952000
CY2020 vygr Deductions To Contract With Customer Assets
DeductionsToContractWithCustomerAssets
46436000
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8012000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
70040000
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
26351000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
43689000
CY2019Q2 vygr Collaborative Arrangement Total Payable Amount
CollaborativeArrangementTotalPayableAmount
20000000.0
CY2020 vygr Patent Costs Incurred
PatentCostsIncurred
500000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020 vygr Common Stock Voting Rights Number Of Vote
CommonStockVotingRightsNumberOfVote
1
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10592520
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9043155
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1313000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3027116
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.24
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14934000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15640000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15710000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14934000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15640000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15710000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5317326
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.98
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1560575
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.87
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
228436
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.15
CY2019Q4 us-gaap Deferred Tax Liabilities Unrealized Gains On Trading Securities
DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
8000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1164387
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
17.33
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5485078
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.77
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1000000.0
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
800000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-180000
CY2018 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
-180000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-180000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
6136000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1502000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
721000
CY2020Q4 vygr Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
13006000
CY2019Q4 vygr Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
9335000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4368000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5157000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1288000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
12176000
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
16805000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.050
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.022
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.021
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.019
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.023
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.080
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.063
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.050
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.362
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.281
CY2020 vygr Effective Income Tax Rate Reconciliation Nondeductible Expense General Business Credit Carryovers Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGeneralBusinessCreditCarryoversPercent
-0.206
CY2019 vygr Effective Income Tax Rate Reconciliation Nondeductible Expense General Business Credit Carryovers Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGeneralBusinessCreditCarryoversPercent
0.094
CY2018 vygr Effective Income Tax Rate Reconciliation Nondeductible Expense General Business Credit Carryovers Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGeneralBusinessCreditCarryoversPercent
0.031
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
CY2020 vygr Percentage Of Maximum Net Operating Loss Carryforward
PercentageOfMaximumNetOperatingLossCarryforward
0.80
CY2016 vygr Number Of Ownership Changes
NumberOfOwnershipChanges
3
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41130000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
49713000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
28173000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
17297000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
776000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
100862000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
100585000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
84866000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
90920000
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1878000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
9852000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
15996000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
9665000
CY2020Q4 us-gaap Deferred Tax Liabilities Unrealized Gains On Trading Securities
DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
8000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
7779000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
84900000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
90900000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-1000000.0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
0
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0

Files In Submission

Name View Source Status
0001558370-21-001865-index-headers.html Edgar Link pending
0001558370-21-001865-index.html Edgar Link pending
0001558370-21-001865.txt Edgar Link pending
0001558370-21-001865-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vygr-20201231.xsd Edgar Link pending
vygr-20201231x10k.htm Edgar Link pending
vygr-20201231x10k006.jpg Edgar Link pending
vygr-20201231x10k007.jpg Edgar Link pending
vygr-20201231x10k009.jpg Edgar Link pending
vygr-20201231x10k010.jpg Edgar Link pending
vygr-20201231x10k012.jpg Edgar Link pending
vygr-20201231x10k013.jpg Edgar Link pending
vygr-20201231x10k015.jpg Edgar Link pending
vygr-20201231x10k017.jpg Edgar Link pending
vygr-20201231x10k_htm.xml Edgar Link completed
vygr-20201231xex10d40.htm Edgar Link pending
vygr-20201231xex21d1.htm Edgar Link pending
vygr-20201231xex23d1.htm Edgar Link pending
vygr-20201231xex31d1.htm Edgar Link pending
vygr-20201231xex31d2.htm Edgar Link pending
vygr-20201231xex32d1.htm Edgar Link pending
vygr-20201231_cal.xml Edgar Link unprocessable
vygr-20201231_def.xml Edgar Link unprocessable
vygr-20201231_lab.xml Edgar Link unprocessable
vygr-20201231_pre.xml Edgar Link unprocessable